The Damaging Impact of PDUFA and Why It Should be Repealed
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
Today's news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
The journal, Nature, reports that the American Association of Publishers (AAP) has hired Eric Dezenhall to fight against open access scientific articles.
An appalling spectacle is taking place in secret in the U.K. whose stench is reminiscent of the Salem witches trials of 1692!
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
The authors argue that recommendations for the expanded use of statins to stave off cardiovascular disease are NOT supported by the evidence.
Neuroscientists are venturing into new areas positing that through attentive thinking (meditating) we can reshape the hard drive of our brains.
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
"Why are scientists coy about publishing negative data?
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
The Times’ humorous profile of JAMA’s editor attempts to trivialize the threat to public health when journals fail to maintain the integrity of science-based medicine.